Development of a Potent Nurr1 Agonist Tool for In Vivo Applications-Reference-Cited by-同舟云学术

Development of a Potent Nurr1 Agonist Tool for In Vivo Applications

Published:2023-04-26 Issue:9 Volume:66 Page:6391-6402
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Vietor Jan¹,Gege Christian²,Stiller Tanja¹,Busch Romy¹,Schallmayer Espen³,Kohlhof Hella²,Höfner Georg¹,Pabel Jörg¹^ORCID,Marschner Julian A.¹,Merk Daniel¹³^ORCID

Affiliation:

1. Department of Pharmacy, Ludwig-Maximilians-Universität (LMU) München, 81377 Munich, Germany

2. Immunic AG, 82166 Gräfelfing, Germany

3. Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany

Funder

H2020 European Research Council

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00415

Reference42 articles.

1. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors

2. NURR1 in Parkinson disease—from pathogenesis to therapeutic potential

3. Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration

4. Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease

5. Nurr1 reduction influences the onset of chronic EAE in mice

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Azologs of the Fatty Acid Mimetic Drug Cinalukast Enable Light‐Induced PPARα Activation;ChemMedChem;2024-08-07

2. Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity;ChemMedChem;2024-08-06

3. Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism;Journal of Medicinal Chemistry;2024-07-31

4. Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified?;Multiple Sclerosis and Related Disorders;2024-07

5. Development of Nurr1 agonists from amodiaquine by scaffold hopping and fragment growing;Communications Chemistry;2024-06-29